Paige Bishop

[Endologix @endologix]

First #DETOURSystem case at @Clara_Maass Medical Center in Belleville, NJ! Congrats to Dr. Neil Poulsen and team on this milestone and win for patients with complex #SFA disease.

Learn about the DETOUR System here: https://t.co/ycFuGmcK9i

#healthcareinnovation #cardiotwitter #endovascularinnovation #medicalinnovation #PTAB

[Endologix @endologix]

Congratulations go out to Dr. Jasrai Gill and his incredible team for completing the first #PTAB at Hackensack Meridian Southern Ocean Medical Center. Thank you for expanding your #PAD toolkit to include the #DETOURSystem so your patients with challenging long, complex SFA lesions can have another option to achieve revascularization without the complications associated with open surgery.

Learn about the DETOUR System here: https://t.co/ycFuGmcK9i

@HMHNewJersey #healthcareinnovation #cardiotwitter #endovascularinnovation #medicalinnovation

[Endologix @endologix]

Major announcement - #Endologix has acquired the Pounce™ Thrombectomy System from Surmodics, Inc.
Pounce, a clinically differentiated mechanical #thrombectomy system for peripheral arterial clot, enables us to support a broader continuum of care for patients with peripheral vascular disease and complements our existing vascular intervention portfolio for the physicians who treat them.

Read the press release to learn more about this exciting expansion: https://t.co/Y3OZZ43MvO

#cardiotwitter #endovascularinnovation #medicalinnovation #endovascular #mycompany #pounceit

[Endologix @endologix]

Curious how #PTAB fits into the #PAD treatment armamentarium? Jaafar Golzar, MD, describes the patient types who could benefit from PTAB with the #DETOURSystem in an interview with @CathLabDigest.

Watch the full interview here: https://t.co/1lRo3vMm0P

Learn about the DETOUR System: https://t.co/ycFuGmcK9i

@JaafGolzar #PeripheralArteryDisease #medtech #healthcareinnovation #medtwitter #cardiotwitter #endovascular #endovascularinnovation #medicalinnovation #percutaneous

[Endologix @endologix]

We're headed to New Orleans from May 26-May 29 for the New Cardiovascular Horizons Annual Meeting. We look forward to engaging with #endovascular experts from around the globe to help advance the treatment of long complex SFA disease, with a focus on how the #DETOURSystem delivers safety and long-term durability for patients with long lesions via fully percutaneous bypass.

To that end, be sure to mark your calendar for a live case presentation at #NCVH2026 on May 29. Prakash Krishnan, MD, will be narrating and sharing pearls as he performs PTAB using the DETOUR System in real-time.

Learn about the DETOUR System here: https://t.co/ycFuGmcK9i

Important Safety Information: https://t.co/6rQM4Cfps1

@NCVHonline #PeripheralArteryDisease #medtech #medicalinnovation #endovascularinnovation #medicaleducation

[Endologix @endologix]

Another great first #DETOURSystem case, this time at Loma Linda University Medical Center – Murrieta with Dr. Amit Karmur. We applaud you for giving patients another endovascular option for their long SFA lesions & restoring flow to the affected extremity.

Learn about the DETOUR System here: https://t.co/ycFuGmcK9i

@LLUHealth #PeripheralArteryDisease #healthcareinnovation #cardiotwitter #endovascularinnovation #medicalinnovation

[Endologix @endologix]

Newport Beach, CA, was the perfect backdrop for our first #PTAB Summit of the year. Innovators in the field came together at the Balboa Bay Resort to learn from Dr. Karthikeshwar Kasirajan and Dr. James (Jim) Joye, the inventor of the #DETOURSystem, about PTAB as a novel #endovascular treatment for patients with long SFA lesions. This peer-to-peer session took a deep dive into patient selection and procedural best practices, provided hands-on learning opportunities, and more.

If you are curious about expanding #PAD toolkit with PTAB, be on the lookout for future professional educational events near you.

Learn about the DETOUR System here: https://t.co/ycFuGmcK9i

#PeripheralArteryDisease #medtech #healthcareinnovation #medtwitter #cardiotwitter #endovascularinnovation #medicalinnovation #percutaneous

[Endologix @endologix]

Milestone achieved! Dr. Rahul Malhotra at Cardiac Surgery Center of Arizona just completed the first #PTAB in an outpatient setting in all of Arizona.

We're excited to see the #DETOURSystem in an outpatient setting and the potential implications on healthcare utilization and patients. Thank you for trailblazing for patients with long SFA lesions!

Learn about the DETOUR System here: https://t.co/ycFuGmcK9i

#healthcareinnovation #cardiotwitter #endovascularinnovation #medicalinnovation

[Endologix @endologix]

Congrats to Dr. David Loran and team for completing the first #PTAB case at @UPMC Harrisburg. This was the 2nd case for Dr. David Loran, but the first at Harrisburg. The patient had previous #endovascular interventions that failed. Dr. Loran finished this case in a little over an hour and was able to restore flow to the lower extremeties using the #DETOURSystem. 👏👏

Learn about the DETOUR System here: https://t.co/ycFuGmcK9i

#PeripheralArteryDisease #medtech #healthcareinnovation #medtwitter #cardiotwitter #endovascularinnovation #medicalinnovation #percutaneous

[Endologix @endologix]

Late-breaking at #SCAI2026: #PTAB delivers strong clinical outcomes irrespective of the number of run-off vessels, making it a promising alternative to open surgical bypass for patients with complex #PAD - even those with just single vessel runoff.

✅ Primary patency at one, two, and three years was similar for patients with one vessel runoff (84.4%, 68.0%, and 52.1%) compared to patients with more than one vessel runoff (82.1%, 68.1%, and 59.5%).*

Read the press release: https://t.co/mtgdKSfliE

Important Safety Information: https://t.co/6rQM4Cfps1

@SCAI #DETOURSystem #PeripheralArteryDisease #medtech #healthcareinnovation #medtwitter #cardiotwitter #endovascularinnovation #medicalinnovation #percutaneous

Disclaimer: The DETOUR System is not approved for use outside of the U.S.

[Endologix @endologix]

Headed to Lousiana for #NCVH2026? Visit us in our booth where we'll be sharing how the #DETOURSystem is redefining the treatment route for complex SFA disease as the first minimally invasive procedure that effectively bypasses long femoropopliteal lesions.

Learn about the DETOUR System here: https://t.co/ycFuGmcK9i

@NCVHonline #PeripheralArteryDisease #medtech #healthcareinnovation #medtwitter #cardiotwitter #endovascularinnovation #medicalinnovation

[Endologix @endologix]

A podium first!
Be there at @CXSymposium as Dainis Krievins, MD, of Latvia presents "Five-year results of the DETOUR PQ bypass: Is there a space for endovascular approach to treat long segment femoral lesions?"

Mark your calendar for this important session where you'll be challenged to rethink the treatment route for complex #SFA disease.

🗓️Tuesday, April 21
⌚️11:06 - 11:12 AM
📍Theatre 1

Learn about the #DETOURSystem here: https://t.co/ycFuGmcK9i

#CX2026 #PeripheralArteryDisease #medtech #healthcareinnovation #medtwitter #cardiotwitter #endovascularinnovation #medicalinnovation #percutaneous #PTAB @ExceLLondon

Disclaimer: The DETOUR System is not approved for use outside of the U.S.

[Endologix @endologix]

Next stop: Philadelphia.
Visit our booth at the Delaware Valley Vascular Society Annual Meeting to see the latest evidence supporting #PTAB with the #DETOURSystem as a safe and durable endovascular intervention for patients with long complex #SFA disease.

Learn about the DETOUR System here: https://t.co/ycFuGmcK9i

@VascularSVS #PeripheralArteryDisease #medtech #healthcareinnovation #medtwitter #cardiotwitter #endovascularinnovation #medicalinnovation #percutaneous

[Endologix @endologix]

We're kicking off on an East Coast tour with the New York Society of Vascular Surgery Spring Meeting. Visit us in the #Endologix booth to learn the latest on the #DETOURSystem, the first fully #percutaneous bypass for long, complex #SFA lesions.

Learn about the DETOUR System here: https://t.co/ycFuGmcK9i

@NewYorkSVS #PeripheralArteryDisease #medtech #healthcareinnovation #medtwitter #cardiotwitter #endovascularinnovation #medicalinnovation

[Endologix @endologix]

Progress for #PAD patients with complex #SFA lesions is happening at Jefferson Abington Hospital! Dr. Jaclyn Milici recently completed her first #PTAB with the #DETOURSystem. Thank you for pushing the boundaries of what's possible for your PAD patients.

Learn about the DETOUR System here: https://t.co/ycFuGmcK9i

@jmiliciDO @TJUHospital
#PeripheralArteryDisease #medtech #healthcareinnovation #medtwitter #cardiotwitter #endovascularinnovation #medicalinnovation #percutaneous

[Endologix @endologix]

Congratulations to Dr. David Loran and team on your first #PTAB case and the first in the entire @UPMC Health System.

It’s through moments like these that patient care continues to evolve. By incorporating the #DETOURSystem into the #PAD treatment toolkit, physicians can expand #endovascular options for patients with long #SFA lesions and offer a new way forward for patients when open surgical bypass is not feasible.

Learn about the DETOUR System here: https://t.co/ycFuGmcK9i

#PeripheralArteryDisease #medtech #healthcareinnovation #medtwitter #cardiotwitter #endovascularinnovation #medicalinnovation #percutaneous

[Endologix @endologix]

A milestone worth celebrating!

Our congratulations go out to Dr. Karthikeshwar Kasirajan on completing his 30th #PTAB case with the #DETOURSystem. We applaud you for embracing this novel endovascular technique — expanding access and bringing new options to patients who need them most.

Interested to know what he's learned along the way? Join Dr. Kasirajan for a live webinar on April 28 for key insights into PTAB patient selection, and for an opportunity to ask your questions live!

Webinar: "Who is the Right Patient? Real-World Selection for DETOUR™ System"
🗓️Tuesday, April 28th | 4:30PM PDT
➡️ Register here: https://t.co/Sef5lwRN97

@SHC_TriValley
#PeripheralArteryDisease #medtech #healthcareinnovation #medtwitter #cardiotwitter #endovascularinnovation #medicalinnovation #percutaneous

[Endologix @endologix]

A great first #PTAB case for Dr. Andrey Espinoza at Advanced Heart and Vascular Institute of Hunterdon - and a great case for teamwork in managing a highly complex revascularization.

A 75-year-old female with a history of five prior lower-extremity interventions presented with a dorsal foot wound secondary to advanced critical limb ischemia (#CLI). Given the complexity of her femoropopliteal disease and extensive prior treatment history, she underwent an #endovascular bypass using PTAB with the #DETOURSystem, successfully traversing previously placed stents and heavily calcified segments.

Learn about the DETOUR System here: https://t.co/ycFuGmcK9i

#PeripheralArteryDisease #medtech #healthcareinnovation #medtwitter #cardiotwitter #endovascularinnovation #medicalinnovation #percutaneous

[Endologix @endologix]

An impactful read in Journal of Critical Limb Ischemia. Karthikeshwar Kasirajan, MD, provides a peer-reviewed case report for using the #DETOURSystem to treat flush in-stent occlusion, reinforcing #PTAB as a less-invasive option than surgical bypass and with comparable revascularization.

Read now: https://t.co/eQRywRoexK

Learn more about the DETOUR System: https://t.co/6vAbZrqqw7

@CLIjournal #PeripheralArteryDisease #PAD #medtech #healthcareinnovation #medtwitter #cardiotwitter #endovascular #endovascularinnovation #medicalinnovation #percutaneous

[Endologix @endologix]

A new meta-analysis provides thought-provoking insight into the performance of #endovascular revascularization in patients with long fem-pop lesions. Not to mention potential implications on clinical-decision making.

Pooled cumulative event rates (95% CI) at 6, 12, 24, and 36 months, respectively, were as follows:

📈Primary patency: 0.85 (95% CI, 0.81-0.89), 0.67 (95% CI, 0.61-0.73), 0.48 (95% CI, 0.38-0.57), and 0.42 (95% CI, 0.33-0.52)
📈Secondary patency: 0.90 (95% CI, 0.85-0.93), 0.84 (95% CI, 0.77-0.89), 0.72 (95% CI, 0.64-0.78), 0.63 (95% CI, 0.52-0.73)
📈Freedom from target lesion revascularization: 0.93 (95% CI, 0.89-0.96), 0.79 (95% CI, 0.74-0.83), 0.68 (95% CI, 0.62-0.73), and 0.63 (95% CI, 0.57-0.69)

Read the full analysis here: https://t.co/RP5SAAH6MW

#PeripheralArteryDisease #interventionalcardiology #medtech #healthcareinnovation #medtwitter #cardiotwitter #endovascularinnovation #medicalinnovation #percutaneousbypass #patientadvocacy #vascularmedicine